Johnson & Johnson Archives - Page 11 of 33

6 drug delivery innovations you need to know

From wearable insulin delivery devices to drug-eluting implants and everything in between, drug delivery innovation never stops.

Vaccines, life-saving therapeutics, vision-correcting drugs and more are being developed and marketed for delivery with all kinds of technologies.

More than a year ago, we compiled a list of eight drug delivery innovations you need to know. With some updates on some of those technologies, plus introductions to others, here are some more impressive developments you should keep an eye on:

1. Needle-free delivery

Vaccines have become a major talking point over the past couple of years amid the COVID-19 pandemic and a number of companies are working on ways to deliver them, as well as other forms of medication, through different avenues.

A major speed bump in vaccine hesitancy can be fear of needles, so the introduction of needle-free drug delivery could make big waves in the space.

Two companies pushing forward with …

The biggest medtech personnel moves so far in 2022

In the ever-changing world of medtech, those who are leading the companies are bound to move around a bit.

At the end of last year, we compiled a list of medtech’s biggest personnel changes in 2021. Throughout just over half of 2022, we’ve already seen a slew of major moves around some of the space’s most powerful players.

Here is a list of some of the biggest personnel changes in medtech so far in 2022:

3M’s healthcare president retires 3M Health Care Business Group President Mojdeh Poul [Image courtesy of 3M]Mojdeh Poul, the president of 3M’s healthcare business, announced in May that she would retire from the position and her retirement was made effective on July 1.

Poul joined 3M in 2011 as the global business VP of critical and chronic care solutions. She later became VP and general manager of the company’s food safety business and president of numerous 3M divisions, including infection prevention, 3M Canada, and sa…

J&J focuses on strengthening MedTech business, dampens M&A talk

Johnson & Johnson (NYSE:JNJ) CEO Joaquin Duato says the company isn’t harping on mergers and acquisitions as it grows its MedTech business.

Speaking on the company’s second-quarter earnings call, Duato emphasized that Johnson & Johnson MedTech, its rebranded medical devices business, has its sights set on strengthening current strongholds and accessing high-growth market segments to accelerate its own growth.

“When it comes to MedTech, the focus continues to be strengthening our current strongholds and also accessing some high-growth market segments to accelerate growth,” Duato said on the call, as transcribed by The Motley Fool. “And the target areas are the ones that we are operating today: high health orthopedics, cardiology, surgery, historically, it’s been a predictor of our success to the extent we were closer to the areas that we have capabilities.”

Johnson & Johnson MedTech saw a 1.1% decrease…

Johnson & Johnson beats The Street in Q2, lowers full-year guidance

Johnson & Johnson (NYSE:JNJ) shares were up before hours on second-quarter results that came in ahead of the consensus forecast.

The New Brunswick, New Jersey-based company posted profits of $4.8 billion, or $1.80 per share, on sales of $24 billion for the quarter ended June 2022, for a 23.3% bottom-line slide on sales growth of 3%.

Adjusted to exclude one-time items, earnings per share were $2.59, 2¢ ahead of Wall Street, where analysts were looking for sales of $23.8 billion.

Johnson & Johnson MedTech, formerly the company’s medical devices segment, experienced a 1.1% decrease in sales, pulling in nearly $6.9 billion in revenues for the three-month period. The company’s adjusted operational sales grew 3.4%, driven primarily by contact lenses and surgical vision products, as well as electrophysiology products, according to a news release.

Growth in the MedTech segment was “partially offset” by COVID-19-related mobi…

J&J EVP, general counsel Michael Ullmann set to retire

Johnson & Johnson (NYSE:JNJ) announced today that, after 33 years, Michael Ullmann will retire as EVP and general counsel.

Ullmann’s retirement will be made effective on Oct. 17, 2022, at which point Elizabeth Forminard will succeed him as EVP and general counsel, as well as take up a position as a member of Johnson & Johnson’s executive committee.

New Brunswick, New Jersey-based Johnson & Johnson said in a news release that Ullann and Forminard will work together during a transition period until the former’s retirement.

Ullmann joined the company as a mergers and acquisitions attorney in 1989 and has held positions of increasing responsibility since, serving as general counsel for the past 11 years. He also served as the executive sponsor for J&J’s Hispanic and Latino employee resource group and as a member of the Leadership Council on Legal Diversity, an organization that works to build a more open and diverse le…

Moon Surgical raises $31.3M for robotic surgery system

Moon Surgical (Paris and San Francisco) announced today that it has raised $31.3 million in Series A funding to expand its team and accelerate the development of its Maestro robotic surgery system.

GT Healthcare Capital & Partners led the round. There was also participation from Johnson & Johnson Innovation – JJDC, Cathay Health — and existing investors including Sofinnova Partners and medtech leaders including Yann Fleureau, Siddarth Satish, Sacha Loiseau and Richard Leparmentier.

“At Moon Surgical, our ambition is to revolutionize minimally invasive surgery through the power of collaborative and adaptive robotics. Our Maestro System can be used in any laparoscopy, in any operating room,” said Anne Osdoit, CEO of Moon Surgical and a partner in Sofinnova Partners’ medtech accelerator, MD Start.

“We are excited to work with our new partners at GT Healthcare, Johnson & Johnson, and Cathay Health as we enter the ne…

Ethicon launches next-gen surgical stapler

The next-gen Echelon 3000 surgical stapler [Image courtesy of Johnson & Johnson’s Ethicon]Johnson & Johnson’s Ethicon today announced the U.S. launch of its next-gen Echelon 3000 stapler.

The Echelon 3000 is digitally-enabled and provides surgeons with simple, one-handed powered articulation, according to the Johnson & Johnson (NYSE:JNJ) company.

The surgical stapler’s creators designed it with 39% greater jaw aperture and a 27% greater articulation span. The idea was to give surgeons better access and control over each transection. The software then provides real-time haptic and audible device feedback so that surgeons can make critical adjustments during procedures.

“Surgical complications often stem from difficult-to-access anatomy and compromised tissue, which this next generation Echelon stapler is specifically designed to address,” said Tom O’Brien, worldwide president of Endomechanical at Ethicon.

<…

FDA clears DePuy Synthes’ Inhance for total shoulder arthroplasty

Johnson & Johnson MedTech’s DePuy Synthes ortho device company announced today that its Inhance system has received FDA clearance for total shoulder arthroplasty.

DePuy Synthes officials say their company is first to market with a fully convertible should arthroplasty system. The new clearance is in addition to the system’s already cleared use in anatomic shoulder arthroplasty and provides surgeons with interoperative flexibility.

The reverse system’s features include:

A 135° neck-shaft angle with lateralized options; A variety of sizing options; 3D laser-printed R/SPEED baseplates and modular Baseplates with central screw and central post options Advanced cross-linked Vitamin E polyethylene for desired wear characteristics and oxidative stability One Step Prep glenoid reamers

“The Inhance shoulder system can be used for an anatomic or reverse shoulder procedure offering the surgeon and OR staff a streamlined and effective shoulder syst…

Johnson & Johnson’s Consumer Health chief to run new stand-alone company

Thibaut Mongon — EVP and Worldwide Chair of Consumer Health at Johnson & Johnson since 2019 — will be CEO of the business when it spins out as a stand-alone company.

J&J (NYSE: JNJ) expects the spinoff to be complete in 2023, subject to legal requirements, including consultation with works councils and employee representatives.

“Thibaut is a visionary and respected global leader, whose consumer-centric mindset has repeatedly propelled the business forward. Under his leadership, the Consumer Health business of Johnson & Johnson has advanced its innovation to reach consumers with products that truly make a difference in their personal health, while simultaneously delivering healthy financial results,” Executive Chair Alex Gorsky said in a news release.

Emergent hid quality problems from FDA, House report concludes

A new Congressional report concluded that Emergent BioSolutions (NYSE:EBS) attempted to hide evidence related to quality problems before informing the FDA that 15 million COVID-19 vaccines were contaminated.

Prepared for Rep. Carolyn Maloney (D-NY) and James E. Clyburn (D-SC), the report from the House and the Select Subcommittee on the Coronavirus Crisis scrutinizes the quality controls in Emergent’s Bayview plant in Baltimore.

In particular, the House report concluded that Emergent workers removed quality-assurance “hold” tags from Johnson & Johnson vaccine batches before an FDA inspection.

The Bayview plant had served as the only U.S. manufacturing site for the J&J COVID-19 vaccine.

The report relies on internal communications from Emergent executives to determine whether the company attempted to elude government oversight.

It also noted that the FDA, J&J and AstraZeneca employees identified problems at the …

Johnson & Johnson MedTech appoints new CFO

Johnson & Johnson MedTech (NYSE:JNJ) announced that Kurt Van den Bosch has been appointed as its CFO, group finance.

Van den Bosch will be a member of Johnson & Johnson’s global finance team, reporting to the company’s EVP and CFO Joe Wolk. Van den Bosch’s role includes providing financial leadership to the global Johnson & Johnson MedTech organization.

He most recently served as area VP of mid-sized markets for J&J MedTech EMEA, overseeing the EMEA business that included the markets of Austria, Belgium, Greece, Israel, Portugal, Switzerland, the Netherlands and Scandinavian countries.

Van den Bosch joined Johnson & Johnson’s Janssen Pharmaceuticals, Belgium, company in 1990 as part of its finance team and has held a range of roles with increasing responsibility since. Before joining J&J MedTech, he was CFO for Janssen EMEA from 2012 to 2014, before being appointed to the role of CFO for global surgery EMEA…

The cloud is transforming medtech: Amazon, Microsoft, Google, J&J, Philips and GE Healthcare leaders explain

[Illustration via Adobe Stock] Leaders in medtech and cloud computing discuss payoffs and potential in device connectivity, product development and cross-industry partnerships.

If knowledge is power, that power comes from a steady stream of information, and we know there’s no shortage of that in healthcare.

The challenge has long been how to capture that information, store it, analyze it and deploy it to improve medical product design, manufacturing and the health of patients.

Then came the cloud, and with it a host of acronyms: software as a service (SaaS), platform as a service (PaaS), infrastructure as a service (IaaS), and — following the same convention — software as a medical device (SaMD).

Over the past few months, Medical Design & Outsourcing connected with leaders in medtech and cloud computing, including the three largest providers of cloud computing services: Amazon (Nasdaq: AMZN), Microsoft (Nasdaq: MSFT) and Google (Nasdaq: GOOGL).…